MedTrace Logo

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2013-11-25

Study results available
· View outcomes & findings →

Summary

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Conditions

  • Thyroid Neoplasms

Interventions

DRUG

AG-013736

AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Canada
  • China
  • Czechia
  • India
  • Italy
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389441 on ClinicalTrials.gov